-
1
-
-
0037616996
-
-
National Cancer Institute. Bethesda, MD
-
Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK (eds): SEER Cancer Statistics Review, 1973-1999, National Cancer Institute. Bethesda, MD, 2002. http://seer.cancer.gov/csr/1973_1999
-
(2002)
SEER Cancer Statistics Review, 1973-1999
-
-
Ries, L.A.G.1
Eisner, M.P.2
Kosary, C.L.3
Hankey, B.F.4
Miller, B.A.5
Clegg, L.6
Edwards, B.K.7
-
2
-
-
0012415819
-
-
Toronto, Canada
-
National Cancer Institute of Canada: Canadian Cancer Statistics, Toronto, Canada, 2002. http://www.ncic.cancer.ca
-
(2002)
Canadian Cancer Statistics
-
-
-
3
-
-
0035881074
-
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
-
Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648, 2001
-
(2001)
J Clin Oncol
, vol.19
, pp. 3635-3648
-
-
Balch, C.M.1
Buzaid, A.C.2
Soong, S.J.3
Atkins, M.B.4
Cascinelli, N.5
Coit, D.G.6
Fleming, I.D.7
Gershenwald, J.E.8
Houghton Jr., A.9
Kirkwood, J.M.10
McMasters, K.M.11
Mihm, M.F.12
Morton, D.L.13
Reintgen, D.S.14
Ross, M.I.15
Sober, A.16
Thompson, J.A.17
Thompson, J.F.18
-
4
-
-
0025058101
-
Chemotherapy for malignant melanoma: Combinations and high doses produce more responses without survival benefit
-
Lakhani S, Selby P, Bliss JM, Perren TJ, Gore ME, McElwain TJ: Chemotherapy for malignant melanoma: Combinations and high doses produce more responses without survival benefit. Br J Cancer 61: 330-334, 1990
-
(1990)
Br J Cancer
, vol.61
, pp. 330-334
-
-
Lakhani, S.1
Selby, P.2
Bliss, J.M.3
Perren, T.J.4
Gore, M.E.5
McElwain, T.J.6
-
5
-
-
0002262637
-
Melanoma
-
De Vita VT, Hellman S, Rosenberg SA (eds) Lippincott. Philadephia
-
Kirkwood JM: Melanoma. In: De Vita VT, Hellman S, Rosenberg SA (eds) Biologic Therapy of Cancer. Lippincott. Philadephia, 1995, pp 388-411
-
(1995)
Biologic Therapy of Cancer
, pp. 388-411
-
-
Kirkwood, J.M.1
-
6
-
-
0031805726
-
Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma
-
Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16: 1752-1759, 1998
-
(1998)
J Clin Oncol
, vol.16
, pp. 1752-1759
-
-
Legha, S.S.1
Ring, S.2
Eton, O.3
Bedikian, A.4
Buzaid, A.C.5
Plager, C.6
Papadopoulos, N.7
-
7
-
-
0032772629
-
Expression of cell cycle regulators in human cutaneous malignant melanoma
-
Tang L, Li G, Tron VA, Trotter MJ, Ho VC: Expression of cell cycle regulators in human cutaneous malignant melanoma. Melanoma Res 9: 148-154, 1999
-
(1999)
Melanoma Res
, vol.9
, pp. 148-154
-
-
Tang, L.1
Li, G.2
Tron, V.A.3
Trotter, M.J.4
Ho, V.C.5
-
8
-
-
0032589240
-
Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells
-
Rizos H, Darmanian AP, Indsto JO, Shannon JA, Kefford RF, Mann GJ: Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells. Melanoma Res 9: 10-19, 1999
-
(1999)
Melanoma Res
, vol.9
, pp. 10-19
-
-
Rizos, H.1
Darmanian, A.P.2
Indsto, J.O.3
Shannon, J.A.4
Kefford, R.F.5
Mann, G.J.6
-
9
-
-
0029665778
-
Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK)2 and CDK4 in human breast carcinoma cells
-
Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ: Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK)2 and CDK4 in human breast carcinoma cells. Cancer Res 56: 2973-2978, 1996
-
(1996)
Cancer Res
, vol.56
, pp. 2973-2978
-
-
Carlson, B.A.1
Dubay, M.M.2
Sausville, E.A.3
Brizuela, L.4
Worland, P.J.5
-
10
-
-
0000602266
-
Inhibition of CDK2, CDK4, and CDK7 by flavopiridol and structural analogues
-
Carlson BA, Pearlstein RA, Naik RG, Sedlacek HH, Sausville EA, Worland PJ: Inhibition of CDK2, CDK4, and CDK7 by flavopiridol and structural analogues (Abstract). Proc Am Assoc Cancer Res 37: 424, 1996
-
(1996)
Proc Am Assoc Cancer Res
, vol.37
, pp. 424
-
-
Carlson, B.A.1
Pearlstein, R.A.2
Naik, R.G.3
Sedlacek, H.H.4
Sausville, E.A.5
Worland, P.J.6
-
11
-
-
0029904810
-
Flavopiridol. A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells
-
Bible KC, Kaufmann SH: Flavopiridol. A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 56: 4856-4861, 1996
-
(1996)
Cancer Res
, vol.56
, pp. 4856-4861
-
-
Bible, K.C.1
Kaufmann, S.H.2
-
12
-
-
0026452974
-
Growth inhibition with reversible cell-cycle arrest of carcinoma cells by flavone L86-8275
-
Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, Czech J, Naik R, Sausville E: Growth inhibition with reversible cell-cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 84: 1736-1749, 1992
-
(1992)
J Natl Cancer Inst
, vol.84
, pp. 1736-1749
-
-
Kaur, G.1
Stetler-Stevenson, M.2
Sebers, S.3
Worland, P.4
Sedlacek, H.5
Myers, C.6
Czech, J.7
Naik, R.8
Sausville, E.9
-
13
-
-
3543031894
-
-
Hoechst Marion Roussel, Inc., Bridgewater, NJ
-
Investigator's Brochure, HMR 1275, 1st edition. Hoechst Marion Roussel, Inc., Bridgewater, NJ 1998
-
(1998)
Investigator's Brochure, HMR 1275, 1st Edition
-
-
-
14
-
-
0032212885
-
Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis
-
Patel V, Senderowicz AM, Pinto D Jr, Igishi T, Raffeld M, Quintanilla-Martinez L, Ensley JF, Sausville EA, Gutkind JS: Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 102: 1674-1681, 1998
-
(1998)
J Clin Invest
, vol.102
, pp. 1674-1681
-
-
Patel, V.1
Senderowicz, A.M.2
Pinto Jr., D.3
Igishi, T.4
Raffeld, M.5
Quintanilla-Martinez, L.6
Ensley, J.F.7
Sausville, E.A.8
Gutkind, J.S.9
-
15
-
-
0032055497
-
Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts
-
Arguello F, Alexander M, Sterry JA, Tudor G, Smith EM, Kalavar NT, Greene JF Jr, Koss W, Morgan CD, Stinson SF, Siford TJ, Alvord WG, Klabansky RL, Sausville EA: Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91: 2482-2490, 1998
-
(1998)
Blood
, vol.91
, pp. 2482-2490
-
-
Arguello, F.1
Alexander, M.2
Sterry, J.A.3
Tudor, G.4
Smith, E.M.5
Kalavar, N.T.6
Greene Jr., J.F.7
Koss, W.8
Morgan, C.D.9
Stinson, S.F.10
Siford, T.J.11
Alvord, W.G.12
Klabansky, R.L.13
Sausville, E.A.14
-
16
-
-
0031670668
-
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor in patients with refractory neoplasms
-
Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG, Sausville EA: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor in patients with refractory neoplasms. J Clin Oncol 16: 2986-2999, 1998
-
(1998)
J Clin Oncol
, vol.16
, pp. 2986-2999
-
-
Senderowicz, A.M.1
Headlee, D.2
Stinson, S.F.3
Lush, R.M.4
Kalil, N.5
Villalba, L.6
Hill, K.7
Steinberg, S.M.8
Figg, W.D.9
Tompkins, A.10
Arbuck, S.G.11
Sausville, E.A.12
-
17
-
-
0033955395
-
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium study
-
Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, Vokes EE: Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium study. J Clin Oncol 18: 371-375, 2000
-
(2000)
J Clin Oncol
, vol.18
, pp. 371-375
-
-
Stadler, W.M.1
Vogelzang, N.J.2
Amato, R.3
Sosman, J.4
Taber, D.5
Liebowitz, D.6
Vokes, E.E.7
-
18
-
-
0035300684
-
Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma
-
Schwartz GK, Ilson D, Saltz L, O'Reilly E, Tong W, Maslak P, Werner J, Perkins P, Stoltz M, Kelsen D: Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 19: 1985-1992, 2001
-
(2001)
J Clin Oncol
, vol.19
, pp. 1985-1992
-
-
Schwartz, G.K.1
Ilson, D.2
Saltz, L.3
O'Reilly, E.4
Tong, W.5
Maslak, P.6
Werner, J.7
Perkins, P.8
Stoltz, M.9
Kelsen, D.10
-
19
-
-
0034900178
-
A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer
-
Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, Muzikansky A, Wright JJ, Lynch TJ Jr, Rollins BJ: A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clinical Cancer Research 7: 1590-1599, 2001
-
(2001)
Clinical Cancer Research
, vol.7
, pp. 1590-1599
-
-
Shapiro, G.I.1
Supko, J.G.2
Patterson, A.3
Lynch, C.4
Lucca, J.5
Zacarola, P.F.6
Muzikansky, A.7
Wright, J.J.8
Lynch Jr., T.J.9
Rollins, B.J.10
-
20
-
-
0036789539
-
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms
-
Tan AR, Headlee D, Messmann R, Sausville EA, Arbuck SG, Murgo AJ, Melillo G, Zhai S, Figg WD, Swain SM, Senderowicz AM: Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 20: 4074-4082, 2002.
-
(2002)
J Clin Oncol
, vol.20
, pp. 4074-4082
-
-
Tan, A.R.1
Headlee, D.2
Messmann, R.3
Sausville, E.A.4
Arbuck, S.G.5
Murgo, A.J.6
Melillo, G.7
Zhai, S.8
Figg, W.D.9
Swain, S.M.10
Senderowicz, A.M.11
-
22
-
-
0034594628
-
New guidelines to evaluate the response to treatments in solid tumors (RECIST guidelines)
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatments in solid tumors (RECIST guidelines). J Natl Cancer Inst 92: 205-216, 2000
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
Verweij, J.7
Van Glabbeke, M.8
Van Oosterom, A.T.9
Christian, M.C.10
Gwyther, S.G.11
-
23
-
-
0034294533
-
Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol
-
Li Y, Chinni SR, Senderowicz AM, Sarkar FH: Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol. Int J Oncol 17: 755-759, 2000
-
(2000)
Int J Oncol
, vol.17
, pp. 755-759
-
-
Li, Y.1
Chinni, S.R.2
Senderowicz, A.M.3
Sarkar, F.H.4
-
24
-
-
0035138482
-
Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cell lines
-
Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, Bates SE: Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cell lines. Clinical Cancer Research 7: 145-152, 2001
-
(2001)
Clinical Cancer Research
, vol.7
, pp. 145-152
-
-
Robey, R.W.1
Medina-Perez, W.Y.2
Nishiyama, K.3
Lahusen, T.4
Miyake, K.5
Litman, T.6
Senderowicz, A.M.7
Ross, D.D.8
Bates, S.E.9
-
25
-
-
0034752936
-
Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol
-
Smith V, Raynaud F, Workman P, Kelland LR: Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol. Molecular Pharmacology 60: 885-893, 2001
-
(2001)
Molecular Pharmacology
, vol.60
, pp. 885-893
-
-
Smith, V.1
Raynaud, F.2
Workman, P.3
Kelland, L.R.4
-
26
-
-
0035120249
-
Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol
-
Kahn ME, Senderowicz A, Sausville EA, Barrett KE: Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol. Clinical Cancer Research 7: 343-349, 2001
-
(2001)
Clinical Cancer Research
, vol.7
, pp. 343-349
-
-
Kahn, M.E.1
Senderowicz, A.2
Sausville, E.A.3
Barrett, K.E.4
-
27
-
-
0344299103
-
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: Does quality of life matter?
-
Bernhard J, Thurlimann B, Schmitz SF, Castiglione-Gertsch M, Cavalli F, Morant R, Fey MF, Bonnefoi H, Goldhirsch A, Hurny C: Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? J Clin Oncol 17: 1651-1653, 1999
-
(1999)
J Clin Oncol
, vol.17
, pp. 1651-1653
-
-
Bernhard, J.1
Thurlimann, B.2
Schmitz, S.F.3
Castiglione-Gertsch, M.4
Cavalli, F.5
Morant, R.6
Fey, M.F.7
Bonnefoi, H.8
Goldhirsch, A.9
Hurny, C.10
-
28
-
-
8244254377
-
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
-
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15: 2403-2413, 1997
-
(1997)
J Clin Oncol
, vol.15
, pp. 2403-2413
-
-
Burris III, H.A.1
Moore, M.J.2
Andersen, J.3
Green, M.R.4
Rothenberg, M.L.5
Modiano, M.R.6
Cripps, M.C.7
Portenoy, R.K.8
Storniolo, A.M.9
Tarassoff, P.10
Nelson, R.11
Dorr, F.A.12
Stephens, C.D.13
Von Hoff, D.D.14
|